Shanghai/August.1st, 2022 — Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ECC4703 in healthy participants… Read More
First regulatory milestone as part of a strategy to advance patient care April 11, 2022 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Truvic Medical, Inc., a wholly owned subsidiary of Imperative Care, Inc., today announced that it has received 510(k) clearance from the U.S. Food and Drug… Read More
MENDHAM, N.J. and WARMINSTER, Pa., December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a… Read More
SHANGHAI, July 28, 2021 /PRNewswire/ — Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1), as a potentially novel therapy for… Read More
By Antios Therapeutics, Inc. on Wednesday, Apr 21, 2021 SAVE 1 to evaluate ATI-2173 in combination with tenofovir (TDF) vs. TDF plus placebo SAVE 1 to include cohort of Hepatitis Delta Virus (HDV) co-infected subjects to assess ATI-2173 activity against HDV MENDHAM, N.J., April 21, 2021 (GLOBE NEWSWIRE) – Antios… Read More
News provided by Clover Biopharmaceuticals Mar 24, 2021, 02:15 ET Over 22,000 participants aged 18 years or older are expected to be enrolled in SPECTRA across Latin America, Asia, Europe and Africa Interim analysis of the primary endpoint expected in the middle of 2021 CHENGDU, China and EMERYVILLE, Calif., March… Read More
Study results expected to be presented in mid-2021 ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today announced that it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus (HBV) infection. The Company… Read More
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge Strong immune response and protection observed with adjuvant systems from GSK and Dynavax led to inclusion of both adjuvants separately into Clover’s ongoing Phase 1 clinical… Read More
February 25, 2020 07:00 ET | Source: Allecra Therapeutics GmbH EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam EXBLIFEP safety profile was comparable to piperacillin-tazobactam SAINT-LOUIS, France and WEIL AM RHEIN, Germany, Feb. 25, 2020 (GLOBE NEWSWIRE) — Allecra Therapeutics today… Read More
ATLANTA, Feb. 12, 2020 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase I clinical trial for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B. The Phase… Read More
